CIA-Linked Investor Helped Quantum Systems Expand in US 
OpenAI Rejects Apple Trade Secret Theft Claims 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
France Targets Shein, Temu With Fast-Fashion Fees 
OpenAI Nears Astra AI Model Launch With Safety Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Add as a preferred source on Google
LIVONIA, Mich., March 13, 2018 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that it will host a conference call and live audio webcast on Thursday, March 15, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2017 and to provide a business update.
| Thursday, March 15 at 4:30pm Eastern Time | |
| Domestic: | (844) 494-0188 |
| International: | +1 (425) 278-9114 |
| Conference ID | 2090268 |
| Webcast: | https://edge.media-server.com/m6/p/bxoocvxs |
A webcast replay will be available on the News & Events section of the Gemphire website for all interested parties following the call and will be archived and available for 90 days.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD. Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151. Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.
Contact:
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987
Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
(734)-245-1700
